Our ambitious near and long term carbon reduction targets covering Scope 1, 2 and 3 emissions have been validated by the Science Based Targets initiative (SBTi).

Achieving these targets will require collaboration across the industry, and we are committed to engaging with our suppliers, partners and customers to collectively reduce the carbon intensity of the animal health industry.

We are developing a holistic nature strategy which will aim to protect biodiversity, minimise water consumption and reduce waste.

We envisage an opportunity to play a leading role in animal health when it comes to setting science based targets for nature and are preparing to report under Taskforce for Nature Related Disclosures (TNFD) from 2026.

We have created a new role of Development and Inclusion Director and have introduced new targets around DE&I as part of our refreshed Sustainability strategy.

By increasing our focus in this area, we believe we can have a positive impact on talent attraction and retention, employee satisfaction and overall business performance.

£62.3 million was invested in R&D last financial year, a record amount for Dechra that represented 7.8% of Group revenue. Within this, our product pipeline continues to have a clear focus on new novel products and lifecycle management of existing products.

After the year end, we acquired Invetx Inc., a biotechnology company specialising in long acting monoclonal antibodies for companion animals. Such therapies help to extend and improve the quality of life in dogs and cats while decreasing the care burden for pet owners, in line with our long term strategy to be an innovation leader in animal health.